Affiliation:
1. Chinese Academy of Medical Sciences & Peking Union Medical College
2. Shandong University
3. Shandong Provincial Hospital Affiliated to Shandong First Medical University
4. Center for Reproductive Medicine, Shandong University
Abstract
Abstract
Objective
Observing pregnancy outcomes of patients who used dual-trigger and single-trigger regimens in different ovarian responders who received ART, and assessing the effectiveness and safety of the regimens to provide insights into the optimization of clinical strategy.
Methods
The clinical profile of 2778 infertile patients who received ART (IVF/ICSI) were reviewed and collected retrospectively. Patients enrolled with different ovarian responses were divided into single-trigger and dual-trigger groups based on different real-world trigger protocols. The baseline characteristics, ovulation induction and pregnancy outcomes of the patients were statistically analyzed.
Results
There were no significant differences in characteristics of the baseline and cycle parameters on the two trigger regimen groups for high responders, normal responders and low responders. The number of oocytes and the oocytes retrieval rate by the dual trigger of normal responders and high responders have increased, but there were no significant differences in pregnancy outcomes (embryo transfer rate, pregnancy rate, live birth rate) between trigger groups. The dual trigger had a lower transplant cancellation rate due to prevention of OHSS: high responders (P = 0.927), normal responders (P = 0.251). In poor responders, there were no cases of transplantation cancellation for OHSS prevention in both groups.
Conclusion
The dual trigger is a relatively effective and safe regimen for patients with high response and normal ovarian response. In patients with poor ovarian response, the evidence for reducing the risk of OHSS is not sufficient. Further validation in larger, well-designed randomized controlled trials on whether dual triggering improves pregnancy outcomes in poor responders is needed.
Publisher
Research Square Platform LLC
Reference22 articles.
1. 1. Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S, Stevens GA. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med. 2012;9(12):e 1001356. doi: 10.1371/journal.pmed.1001356.
2. 2. Albeitawi S, Marar EA, Reshoud FA, Hamadneh J, Hamza R, Alhasan G, Omeish H, Vigano P. Dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves oocyte yield in normal responders on GnRH-antagonist cycles. JBRA Assist Reprod. 2022 Jan 17;26(1): 28–32. doi:10.5935/1518-0557.20210039. Gonen Y, Balakier H, Powell W, Casper RF. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab. 1990 Oct;71(4):918 − 22. doi: 10.1210/jcem-71-4-918.
3. 4. Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod, 2000;15(9): 1965–1968. doi: 10.1093/humrep/15.9.1965.
4. 5. JIAO Min-jie, ZHANG Yun-shan, ZHANG Yin-feng. Progression in the use of gonadotropin-releasing hormone antagonists in controlled ovarian hyperstimulation. Shandong Medical Journal. 2016;56(20): 100–102.
5. 6. Marci R, Graziano A, Lo Monte G, Piva I, Soave I, Marra E, Lisi F, Moscarini M, Caserta D. GnRH antagonists in assisted reproductive techniques: a review on the Italian experience. Eur Rev Med Pharmacol Sci. 2013 Apr;17(7):853 − 73.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献